These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33439469)

  • 1. Hyperuricaemia, gout and allopurinol in the CKD Queensland registry.
    Jeyaruban A; Hoy W; Cameron A; Healy H; Wang Z; Zhang J; Mallett A
    J Nephrol; 2021 Jun; 34(3):753-762. PubMed ID: 33439469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
    Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
    Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
    Kim SH; Lee SY; Kim JM; Son CN
    Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol initiation and all-cause mortality in the general population.
    Dubreuil M; Zhu Y; Zhang Y; Seeger JD; Lu N; Rho YH; Choi HK
    Ann Rheum Dis; 2015 Jul; 74(7):1368-72. PubMed ID: 24665118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
    Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
    Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of allopurinol in chronic kidney disease.
    Thurston MM; Phillips BB; Bourg CA
    Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study.
    Wei J; Choi HK; Neogi T; Dalbeth N; Terkeltaub R; Stamp LK; Lyu H; McCormick N; Niu J; Zeng C; Lei G; Zhang Y
    Ann Intern Med; 2022 Apr; 175(4):461-470. PubMed ID: 35073156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
    Mu Z; Wang J; Wang W; Lv W; Chen Y; Wang F; Zhao Y; Dong B; Wang Y; Wang Z
    Int J Rheum Dis; 2020 Aug; 23(9):1145-1151. PubMed ID: 32483927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.
    Jing J; Kielstein JT; Schultheiss UT; Sitter T; Titze SI; Schaeffner ES; McAdams-DeMarco M; Kronenberg F; Eckardt KU; Köttgen A;
    Nephrol Dial Transplant; 2015 Apr; 30(4):613-21. PubMed ID: 25395390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
    Kim HW; Joo YS; Yun HR; Kim JY; Jhee JH; Roh YH; Park JT; Chang TI; Yoo TH; Kang SW; Han SH
    Rheumatology (Oxford); 2022 Nov; 61(11):4314-4323. PubMed ID: 35139160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease in gout in a managed care setting.
    Fuldeore MJ; Riedel AA; Zarotsky V; Pandya BJ; Dabbous O; Krishnan E
    BMC Nephrol; 2011 Aug; 12():36. PubMed ID: 21812963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol Against Progression of Chronic Kidney Disease.
    Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
    Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
    Ting K; Gill TK; Keen H; Tucker GR; Hill CL
    Intern Med J; 2016 May; 46(5):566-73. PubMed ID: 26765205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study.
    Bathini L; Garg AX; Sontrop JM; Weir MA; Blake PG; Dixon SN; McArthur E; Muanda FT
    Am J Kidney Dis; 2022 Dec; 80(6):730-739. PubMed ID: 35644439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.